{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:32:01Z","timestamp":1778049121208,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T00:00:00Z","timestamp":1330387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11255-012-0144-x","type":"journal-article","created":{"date-parts":[[2012,2,27]],"date-time":"2012-02-27T11:50:16Z","timestamp":1330343416000},"page":"793-798","source":"Crossref","is-referenced-by-count":7,"title":["In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors"],"prefix":"10.1007","volume":"44","author":[{"given":"Enis","family":"Coskuner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Cevik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alp","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozdal","family":"Dillioglugil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"At\u0131f","family":"Akdas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,28]]},"reference":[{"issue":"1","key":"144_CR1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10147-006-0552-y","volume":"11","author":"H Kitamura","year":"2006","unstructured":"Kitamura H, Tsukamoto T (2006) Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol 11(1):28\u201337. doi: 10.1007\/s10147-006-0552-y","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"144_CR2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","volume":"130","author":"NM Heney","year":"1983","unstructured":"Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR (1983) Superficial bladder cancer: progression and recurrence. J Urol 130(6):1083\u20131086","journal-title":"J Urol"},{"issue":"2","key":"144_CR3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF02201977","volume":"15","author":"HW Herr","year":"1997","unstructured":"Herr HW (1997) Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 15(2):84\u201388","journal-title":"World J Urol"},{"issue":"6","key":"144_CR4","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","volume":"13","author":"HW Herr","year":"1995","unstructured":"Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13(6):1404\u20131408","journal-title":"J Clin Oncol"},{"issue":"3","key":"144_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000472760","volume":"13","author":"F Pagano","year":"1987","unstructured":"Pagano F, Garbeglio A, Milani C, Bassi P, Pegoraro V (1987) Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 13(3):145\u2013149","journal-title":"Eur Urol"},{"issue":"10","key":"144_CR6","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2102::AID-CNCR31>3.0.CO;2-U","volume":"86","author":"L Cheng","year":"1999","unstructured":"Cheng L, Neumann RM, Bostwick DG (1999) Papillary urothelial neoplasms of low malignant potential. Cancer 86(10):2102\u20132108","journal-title":"Cancer"},{"issue":"1","key":"144_CR7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158(1):62\u201367. doi: 10.1097\/00005392-199707000-00017","journal-title":"J Urol"},{"issue":"6","key":"144_CR8","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0022-5347(05)68075-5","volume":"162","author":"B Leblanc","year":"1999","unstructured":"Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM, Mauffette F, Faucher R, Perreault JP (1999) Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 162(6):1946\u20131950","journal-title":"J Urol"},{"issue":"6","key":"144_CR9","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/S0022-5347(01)66691-6","volume":"154","author":"E Rintala","year":"1995","unstructured":"Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O (1995) Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol 154(6):2050\u20132053","journal-title":"J Urol"},{"issue":"5","key":"144_CR10","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","volume":"164","author":"KC Halling","year":"2000","unstructured":"Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O\u2019Kane DJ, Seelig SA, Lieber MM, Jenkins RB (2000) A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164(5):1768\u20131775","journal-title":"J Urol"},{"issue":"7","key":"144_CR11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","volume":"293","author":"HB Grossman","year":"2005","unstructured":"Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810\u2013816. doi: 10.1001\/jama.293.7.810","journal-title":"JAMA"},{"issue":"3","key":"144_CR12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/01.ju.0000048983.83079.4c","volume":"169","author":"C Pfister","year":"2003","unstructured":"Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O, Beurton D, Coulange C, Rambeaud JJ (2003) Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 169(3):921\u2013924. doi: 10.1097\/01.ju.0000048983.83079.4c","journal-title":"J Urol"},{"issue":"2","key":"144_CR13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000474443","volume":"31","author":"N Miyanaga","year":"1997","unstructured":"Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, Koiso K, Kobayashi M, Koyama A, Takahashi T (1997) Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 31(2):163\u2013168","journal-title":"Eur Urol"},{"issue":"2B","key":"144_CR14","first-page":"1169","volume":"20","author":"V Menendez","year":"2000","unstructured":"Menendez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, Talbot-Wright R (2000) Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder. Anticancer Res 20(2B):1169\u20131172","journal-title":"Anticancer Res"},{"issue":"2 Pt 1","key":"144_CR15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0022-5347(01)65851-8","volume":"156","author":"MS Soloway","year":"1996","unstructured":"Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL (1996) Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156(2 Pt 1):363\u2013367","journal-title":"J Urol"},{"issue":"2\u20133","key":"144_CR16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1615\/CritRevEukarGeneExpr.v6.i2-3.50","volume":"6","author":"SK Keesee","year":"1996","unstructured":"Keesee SK, Briggman JV, Thill G, Wu YJ (1996) Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 6(2\u20133):189\u2013214","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"4","key":"144_CR17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/S0022-5347(01)65569-1","volume":"156","author":"GA Carpinito","year":"1996","unstructured":"Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL (1996) Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 156(4):1280\u20131285","journal-title":"J Urol"},{"issue":"1","key":"144_CR18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2001.19.1.94","volume":"19","author":"F Rabbani","year":"2001","unstructured":"Rabbani F, Perrotti M, Russo P, Herr HW (2001) Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. J Clin Oncol 19(1):94\u2013100","journal-title":"J Clin Oncol"},{"issue":"6","key":"144_CR19","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0022-5347(17)41291-2","volume":"141","author":"J Oldbring","year":"1989","unstructured":"Oldbring J, Glifberg I, Mikulowski P, Hellsten S (1989) Carcinoma of the renal pelvis and ureter following bladder carcinoma: frequency, risk factors and clinicopathological findings. J Urol 141(6):1311\u20131313","journal-title":"J Urol"},{"issue":"2","key":"144_CR20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1040-8428(03)00079-9","volume":"47","author":"Z Kirkali","year":"2003","unstructured":"Kirkali Z, Tuzel E (2003) Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol 47(2):155\u2013169","journal-title":"Crit Rev Oncol Hematol"},{"key":"144_CR21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging manual","author":"FL Greene","year":"2002","unstructured":"Greene FL, American Joint Committee on Cancer, American Cancer Society (2002) AJCC cancer staging manual, 6th edn. Springer, New York, pp 335\u2013340","edition":"6"},{"issue":"12","key":"144_CR22","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22(12):1435\u20131448","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"144_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1464-410x.2000.00467.x","volume":"85","author":"MP Wright","year":"2000","unstructured":"Wright MP, Jones DJ (2000) Surveillance for bladder cancer: the management of 4.8 million people. South-west Urologists. BJU Int 85(4):431\u2013433","journal-title":"BJU Int"},{"issue":"3","key":"144_CR24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477. doi: 10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"issue":"8","key":"144_CR25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/jnci\/95.8.588","volume":"95","author":"D Schrag","year":"2003","unstructured":"Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95(8):588\u2013597","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"144_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","volume":"61","author":"Y Lotan","year":"2003","unstructured":"Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61(1):109\u2013118","journal-title":"Urology"},{"key":"144_CR27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/03008880802283953","volume":"218","author":"EC Zwarthoff","year":"2008","unstructured":"Zwarthoff EC (2008) Detection of tumours of the urinary tract in voided urine. Scand J Urol Nephrol 218:147\u2013153. doi: 10.1080\/03008880802283953","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"144_CR28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2011.05.053","volume":"60","author":"D Tilki","year":"2011","unstructured":"Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Roupret M, Shariat SF, Zlotta AR (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60(3):484\u2013492. doi: 10.1016\/j.eururo.2011.05.053","journal-title":"Eur Urol"},{"issue":"3","key":"144_CR29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eururo.2003.10.020","volume":"45","author":"SF Shariat","year":"2004","unstructured":"Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45(3):304\u2013313. doi: 10.1016\/j.eururo.2003.10.020","journal-title":"Eur Urol"},{"issue":"3","key":"144_CR30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.295.3.299","volume":"295","author":"HB Grossman","year":"2006","unstructured":"Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3):299\u2013305. doi: 10.1001\/jama.295.3.299","journal-title":"JAMA"},{"issue":"1","key":"144_CR31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.urology.2010.04.059","volume":"77","author":"EC Hwang","year":"2011","unstructured":"Hwang EC, Choi HS, Jung SI, Kwon DD, Park K, Ryu SB (2011) Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology 77(1):154\u2013159. doi: 10.1016\/j.urology.2010.04.059","journal-title":"Urology"},{"issue":"2","key":"144_CR32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/0970-1591.82844","volume":"27","author":"R Ayyathurai","year":"2011","unstructured":"Ayyathurai R, Soloway MS (2011) Monitoring of the upper urinary tract in patients with bladder cancer. Indian J Urol 27(2):238\u2013244. doi: 10.4103\/0970-1591.82844","journal-title":"Indian J Urol"},{"issue":"6","key":"144_CR33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","volume":"47","author":"BW Rhijn van","year":"2005","unstructured":"van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47(6):736\u2013748. doi: 10.1016\/j.eururo.2005.03.014","journal-title":"Eur Urol"},{"issue":"2","key":"144_CR34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000330246","volume":"87","author":"M Jovanovic","year":"2011","unstructured":"Jovanovic M, Soldatovic I, Janjic A, Vuksanovic A, Dzamic Z, Acimovic M, Hadzi-Djokic J (2011) Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. Urol Int 87(2):134\u2013137. doi: 10.1159\/000330246","journal-title":"Urol Int"},{"issue":"6","key":"144_CR35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.eururo.2005.09.002","volume":"48","author":"PM Moonen","year":"2005","unstructured":"Moonen PM, Kiemeney LA, Witjes JA (2005) Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur Urol 48(6):951\u2013956. doi: 10.1016\/j.eururo.2005.09.002","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-012-0144-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-012-0144-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-012-0144-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T15:50:02Z","timestamp":1561391402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-012-0144-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,28]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["144"],"URL":"https:\/\/doi.org\/10.1007\/s11255-012-0144-x","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,28]]}}}